Aptamers have gained significant momentum over the past decade. It's worth noting that in 2005, Macugen became the first and only aptamer drug approved by the USFDA for the treatment of age-related macular degeneration (AMD). More than 15 million people have been reported to have AMD in the US alone, with 200,000 cases per year across North America. This indicates a large unmet patient need...